Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 14;13(10):2071.
doi: 10.3390/v13102071.

Feasibility and Effectiveness Assessment of SARS-CoV-2 Antigenic Tests in Mass Screening of a Pediatric Population and Correlation with the Kinetics of Viral Loads

Affiliations

Feasibility and Effectiveness Assessment of SARS-CoV-2 Antigenic Tests in Mass Screening of a Pediatric Population and Correlation with the Kinetics of Viral Loads

Marcello Lanari et al. Viruses. .

Abstract

The gold standard for diagnosis of SARS-CoV-2 infection has been nucleic acid amplification tests (NAAT). However, rapid antigen detection kits (Ag-RDTs), may offer advantages over NAAT in mass screening, generating results in minutes, both as laboratory-based test or point-of-care (POC) use for clinicians, at a lower cost. We assessed two different POC Ag-RDTs in mass screening versus NAAT for SARS-CoV-2 in a cohort of pediatric patients admitted to the Pediatric Emergency Unit of IRCCS-Polyclinic of Sant'Orsola, Bologna (from November 2020 to April 2021). All patients were screened with nasopharyngeal swabs for the detection of SARS-CoV-2-RNA and for antigen tests. Results were obtained from 1146 patients. The COVID-19 Ag FIA kit showed a baseline sensitivity of 53.8% (CI 35.4-71.4%), baseline specificity 99.7% (CI 98.4-100%) and overall accuracy of 80% (95% CI 0.68-0.91); the AFIAS COVID-19 Ag kit, baseline sensitivity of 86.4% (CI 75.0-93.9%), baseline specificity 98.3% (CI 97.1-99.1%) and overall accuracy of 95.3% (95% CI 0.92-0.99). In both tests, some samples showed very low viral load and negative Ag-RDT. This disagreement may reflect the positive inability of Ag-RDTs of detecting antigen in late phase of infection. Among all cases with positive molecular test and negative antigen test, none showed viral loads > 106 copies/mL. Finally, we found one false Ag-RDTs negative result (low cycle thresholds; 9 × 105 copies/mL). Our results suggest that both Ag-RDTs showed good performances in detection of high viral load samples, making it a feasible and effective tool for mass screening in actively infected children.

Keywords: COVID-19; SARS-CoV-2; children; mass screening; rapid antigenic test; real time RT-PCR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
On the left (A), ROC curve for COVID-19 Ag FIA Ag-RDT, compared to real time RT-PCR on the right (B), ROC curve for AFIAS COVID-19 Ag compared to real time RT-PCR. On the x axis, 1-specificity; on y axis, sensitivity.
Figure 2
Figure 2
BOX Plot comparing cut-off index (COI) groups with viral loads. Horizontal lines represent mean, blue squares account for the interquartile range and vertical bars represent the lower and upper limits of values (range). Group 1, COI < 1; Group 2, 1 ≤ COI < 12 and Group 3, COI ≥ 12.

Similar articles

Cited by

References

    1. European Centre for Disease Prevention and Control . COVID-19 Testing Strategies and Objectives. ECDC; Stockholm, Sweden: 2020. [(accessed on 1 July 2021)]. Available online: https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-strateg....
    1. WHO Laboratory Testing for Coronavirus Disease (COVID-19) in Suspected Human Cases: Interim Guidance, 19 March 2020. [(accessed on 1 July 2021)]. Available online: https://apps.who.int/iris/handle/10665/331501.
    1. European Centre for Disease Prevention and Control/European Agency for Safety and Health at Work . Considerations on the Use of Rapid Antigen Detection (Including Self) Tests for SARS-CoV-2 in Occupational Settings. ECDC/EU-OSHA; Stockholm, Sweden: Bilbao, Spain: May 6, 2021. [(accessed on 1 July 2021)]. Available online: https://www.ecdc.europa.eu/en/publications-data/considerations-use-rapid....
    1. European Centre for Disease Prevention and Control . Options for the Use of Rapid Antigen Tests for COVID-19 in the EU/EEA and the UK. ECDC; Stockholm, Sweden: 2020. [(accessed on 1 July 2021)]. Available online: https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antige....
    1. Aggiornamento Della Definizione di Caso COVID-19 e Strategie di Testing e Screening—AGENAS. [(accessed on 1 July 2021)]; Available online: https://www.agenas.gov.it/comunicazione/primo-piano/1795-aggiornamento-d....